Download as PDF
PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes & Obesity
Vancouver, British Columbia: PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is pleased to announce that it has successfully designed, screened and shortlisted a panel of smart-siRNA constructs with potent gene silencing activity (in vitro) in its Dual Gene Therapy Research Program.
This further update to the Company’s Dual Gene Therapy Program, (see earlier release on January 14, 2020), is an important and fundamental aspect which involves deriving Smart-siRNA constructs, effective in downregulating the Company’s target gene of interest, in type 2 diabetes and obesity.
The Company is very pleased to confirm that it has now shortlisted a panel of Smart-siRNA constructs considered novel in their sequence and chemistry. The panel of Smart-siRNA constructs incorporate a proprietary chemistry, adding to their novelty. In the next phase, this construct’s biostability will be essential for assessment in preclinical (mice) models of type 2 diabetes and obesity.
The Company can confirm that a number of siRNA drug delivery systems were evaluated in a 3-dimensional liver tissue assay. The 3D liver tissue assay mimics the 3D architecture and microenvironment of the liver, so it is closer to the real-life biological environment than the 2D testing. Ongoing work aims to determine the optimal drug delivery technology with the Smart-siRNA with the desirable properties, including biostability, the release of the siRNA cargo when exposed to physiological intracellular conditions and no evidence of cellular toxicity.
The Company may consider filing a patent application to protect the siRNA sequences, the Smart-siRNA constructs and related intellectual property arising from this Program.
The Company’s President and Chief Scientific Officer, Dr. Makarand Jawadekar, commented, “We are very happy with the progress of our Programs to date with UniQuest. The outcomes from this Program will definitely add IP to PreveCeutical’s growing IP portfolio, enhancing our “out-licensing” technologies strategy with bigger Pharma companies and helping their commercialization of new products”.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences. The Company’s current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations firstname.lastname@example.org
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the completion of one aspect of the current phase of the Dual Gene Therapy Program, the efficacy of the Company’s products, matters related to the Company’s current and planned research and development programs, including the Dual Gene Therapy Program, the efficacy of the panel of siRNA constructs and the efficacy, biostability and potency of the Smart-siRNAs, the Company’s anticipated future business plans and its prospect of success in executing thereon. Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations and research and development activities (including in respect of the successful completion of the Dual Gene Therapy Program and one aspect of its current phase), performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the completion of the Dual Gene Therapy Program and one aspect of its current phase, actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, including the Dual Gene Therapy Program, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology, pharmaceutical or cannabis industry may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.